 January 30, 2008
|
High Rate of Bone Problems in French HIV Patients
French researchers have found rates of serious bone weakness in HIV-positive patients, particularly HIV-positive men, to be many times higher than in the general population’s, according to a new study published in the January 30 issue of AIDS.
|
|
|
Selzentry May Hold Promise for HIV Prevention
Pfizer announced today that it is offering the International Partnership for Microbicides (IPM) a royalty-free license to develop the antiretroviral drug Selzentry (maraviroc) as a microbicide to prevent HIV transmission.
|
|
|
January 29, 2008
|
DHHS Issues Changes to U.S. Treatment Guidelines
An updated version of the United States Department of Health and Human Services’ (DHHS) Guidelines for the use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents was published online today and contains some important changes to the lineup of antiretroviral drugs recommended for use by people beginning HIV treatment for the first time.
|
|
|
Treatment Interruptions Lower Quality of Life in SMART Trial
HIV-positive people report that the quality of their lives is better when they’re on treatment, compared with when they're taking a drug holiday, according to new data from a sub-study of a large international clinical trial published in the February 1 issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS).
|
|
|
January 28, 2008
|
Swiss Study Finds Less Lipodystrophy in Recent Years
People with HIV in Switzerland who started antiretroviral treatment after 2003 had less lipodystrophy—defined in this study as either fat loss in the face and limbs, fat gain in the trunk, or both—than those who started treatment between 2000 and 2002, say the authors of a new study published online by the British journal HIV Medicine.
|
|
|
| January 25, 2008
|
January 23, 2008
|
Antiretrovirals Significantly Increase Survival in HIV-Positive Children
HIV-positive children treated with a triple-combination antiretroviral regimen have a significant survival advantage, compared with children receiving less effective drug regimens or no antiretrovirals, according to the authors of a new study published in the February 15 issue of Clinical Infectious Diseases.
|
|
|
| January 22, 2008
|
January 18, 2008
|
Kaletra Monotherapy Disappoints
Contrary to the encouraging findings of several small studies, newly reported data conclude that Kaletra (lopinavir/ritonavir) monotherapy is not a durable treatment option for HIV-positive people.
|
|
|
January 17, 2008
|
Low-Dose Interferon Shows Potential for Hep C
A lower dose of PEG-Intron (peginterferon alfa-2b) may be just as effective against hepatitis C virus (HCV) infection as the standard dose of PEG-Intron, according to data announced this week by Schering Plough from their IDEAL study.
|
|
|
January 16, 2008
|
Acid Reflux Meds Allowed With Reyataz
Reyataz (atazanavir) can now be safely used in some circumstances with stomach-acid-reducing proton-pump inhibitors (PPIs), a drug class formerly prohibited with Reyataz, according to recent update to the protease inhibitor’s packaging information authorized by the U.S. Food and Drug Administration.
|
|
|
January 15, 2008
|
New Multi-Drug-Resistant Staph Infections Plaguing Gay Men
Researchers have identified a multiple-drug-resistant strain of methicillin-resistant staphylococcus aureus (MRSA) that is occurring much more frequently among gay men in San Francisco and Boston than in the general population, as well as evidence that the new MRSA can be transmitted sexually.
|
|
|
Low Testosterone Increases Bone-Fracture Risk
Low blood testosterone levels in men over 60 significantly increased their risk of having a bone fracture, according to the authors of a study published in the January 14 issue of the Archives of Internal Medicine.
|
|
|
January 14, 2008
|
Zetia Doesn’t Reduce Artery-Clogging Plaques
Adding Zetia (ezetimibe) to another anti-cholesterol drug, the statin Zocor (simvastatin), did not provide additional protection from harmful artery-blocking fatty plaques, according to a study reported by Forbes.com and other media outlets.
|
|
|
HIV Blocking Proteins Found in Dendritic Cells
Researchers at the University of California Los Angeles (UCLA) have found that two proteins inside dendritic cells stop the virus from “budding,” thus protecting other cells from being infected.
|
|
|
| January 11, 2008
|
January 10, 2008
|
More Heart and Kidney Problems in Treated African Americans
African Americans were more likely to experience serious heart- and kidney-related side effects than Caucasians after starting antiretroviral therapy, and women had more anemia than men, say authors of a study published in the Journal of Acquired Immune Deficiency Syndromes (JAIDS).
|
|
|
January 09, 2008
|
Hepatitis B Revaccination Effective in People With HIV
Revaccinating with a double dose of the hepatitis B virus (HBV) vaccine is effective in at least half of people with HIV who did not respond to an initial round of immunization injections, say researchers of a study published in the January 15 issue of the Journal of Infectious Diseases.
|
|
|
January 08, 2008
|
Following Treatment Guidelines Generates Best Results
HIV-positive women whose doctors followed federal treatment guidelines faired far better in terms of CD4 count and viral load than women whose doctors put them on treatment regimens that were not recommended or covered by those guidelines, say researchers of a study published in the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
January 07, 2008
|
Antiretrovirals Don’t Increase Heart Disease Risk
The use of antiretroviral drugs was found to have a significant benefit in overall survival without any increase in heart disease risks, say researchers of a large study published in the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
Drug Interaction Caution With Crestor and Kaletra
Kaletra (lopinavir/ritonavir) can significantly increase blood levels of Crestor (rosuvastatin)—one of the most effective drugs used to lower high cholesterol—say researchers of a study published in the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
January 04, 2008
|
Potential Drug Interaction Between Sustiva and Dilantin
The anticonvulsant Dilantin (phenytoin) can drastically reduce levels of the HIV drug efavirenz—found in Sustiva/Stocrin and Atripla—in the blood when both medications are used together, according to an article published by AIDSmap reviewing a case report in the January 2 issue of AIDS.
|
|
|
January 03, 2008
|
Peripheral Arterial Disease Risk Found in People With HIV
HIV-positive people face an increased risk of heart attacks and strokes due to clogging of the major blood vessels, and two studies have found variable rates of a related condition, peripheral artery disease (PAD), in two groups of HIV-positive people.
|
|
|
January 02, 2008
|
Antiretroviral Therapy Reduces HIV in Lungs
Antiretroviral therapy significantly reduces HIV levels in the lungs and may potentially reduce the high risk of chronic obstructive pulmonary disease (COPD) and other respiratory illnesses documented in people living with HIV, say researchers of a study published in the January 1 issue of the Journal of Infectious Diseases.
|
|
|
|
